Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma
NCT02849366 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2019-09-12
Summary
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent sarcoma.
Conditions
- Recurrent Adult Soft Tissue Sarcoma
Interventions
- DEVICE
-
Cryosurgery
Percutaneous ablation under CT or ultrasound guidance
- BIOLOGICAL
-
NK immunotherapy
Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Sponsors & Collaborators
-
Shenzhen Hank Bioengineering Institute
collaborator OTHER -
Fuda Cancer Hospital, Guangzhou
lead OTHER
Principal Investigators
-
Jibing Chen, MD, PhD · Fuda Cancer Hospital, Guangzhou
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-01
- Primary Completion
- 2017-07-01
- Completion
- 2019-07-01
Countries
- China
Study Locations
More Related Trials
-
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
NCT02845856 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
NCT03007836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Immunotherapy Targeting Sarcomas
NCT04433221 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Mix Vaccine for Metastatic Sarcoma Patients
NCT03357315 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
NCT02857920 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
NCT03930498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
NCT06688760 ·Status: RECRUITING ·Phase: NA
-
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
NCT05385926 ·Status: RECRUITING ·Phase: PHASE2
-
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
NCT03462316 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
NCT02886897 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
NCT06062927 ·Status: RECRUITING
-
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
NCT06912711 ·Status: RECRUITING ·Phase: PHASE2
-
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
NCT05602415 ·Status: UNKNOWN ·Phase: PHASE2
-
High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer
NCT03008330 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
NCT05774275 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer
NCT02734524 ·Status: UNKNOWN ·Phase: PHASE2
-
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780 ·Status: RECRUITING ·Phase: NA
-
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
NCT07188584 ·Status: RECRUITING ·Phase: PHASE3
-
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
NCT07342322 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
NCT04807140 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
NCT06080854 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
NCT06284226 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas
NCT06644287 ·Status: RECRUITING
-
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer
NCT03554395 ·Status: WITHDRAWN ·Phase: PHASE2